CXCL10 and neoplasm: Notably, RT plus Y332D markedly enhanced the infiltration of CXCR3+ T, CXCR3+ CD8+ T, CXCR3+ CD4+ T, and CXCR3+ NK cells versus either monotherapies or vehicle (Figure 6e–g), potentially due to the recruitment of CXCR3‐positive lymphocytes into the tumor by CXCL10 secreted by tumor cells, which is promoted by RT.